---
title: "If You Invested $1000 In TransMedics Group Stock 5 Years Ago, You Would Have This Much Today"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285746125.md"
description: "TransMedics Group (NASDAQ:TMDX) has delivered an annualized return of 24.1% over the past 5 years, outperforming the market by 11.88%. An investment of $1000 in TMDX stock five years ago would now be worth $2,971.67, reflecting the significant impact of compounded returns. The company's current market capitalization stands at $2.52 billion."
datetime: "2026-05-08T15:00:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285746125.md)
  - [en](https://longbridge.com/en/news/285746125.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285746125.md)
---

# If You Invested $1000 In TransMedics Group Stock 5 Years Ago, You Would Have This Much Today

TransMedics Group (NASDAQ:TMDX) has outperformed the market over the past 5 years by 11.88% on an annualized basis producing an average annual return of 24.1%. Currently, TransMedics Group has a market capitalization of $2.52 billion.

**Buying $1000 In TMDX:** If an investor had bought $1000 of TMDX stock 5 years ago, it would be worth **$2,971.67** today based on a price of $72.90 for TMDX at the time of writing.

### TransMedics Group's Performance Over Last 5 Years

![comp_fig](https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1778252438_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg)

Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.

_This article was generated by Benzinga's automated content engine and reviewed by an editor._

### Related Stocks

- [TMDX.US](https://longbridge.com/en/quote/TMDX.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)

## Related News & Research

- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)
- [Precigen Q1 revenue beats estimates on PAPZIMEOS launch](https://longbridge.com/en/news/286311056.md)
- [Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT](https://longbridge.com/en/news/286414681.md)
- [Regenxbio's muscle disorder therapy meets main goal in late-stage study](https://longbridge.com/en/news/286406339.md)
- [US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug](https://longbridge.com/en/news/286394551.md)